Financial Performance - Revenue increased by 8% year-over-year, reaching $408.2 million in 3Q25 compared to $376.4 million in 3Q24[14] - Adjusted EBITDA decreased to $37.7 million in 3Q25 from $46.6 million in 3Q24[14] - The combined Senior and Healthcare Services Revenue-to-Customer Acquisition Cost (Rev-to-CAC) multiple was 5.8x[14] - The company anticipates full year 2025 revenue between $1500 billion and $1575 billion, representing a 16% year-over-year increase at the midpoint[38] - The company anticipates full year 2025 Adjusted EBITDA between $115 million and $140 million, representing a 9% year-over-year increase at the midpoint[38] - The company anticipates full year 2025 Net Income (Loss) between $(1) million and $28 million, representing a 140% year-over-year increase at the midpoint[38] Senior Segment - Approved Medicare Advantage (MA) policies exceeded forecasts, despite a 26% reduction in the number of agents, resulting in only a 10% decrease in MA policies[14] - Strong close rates contributed to robust performance and Adjusted EBITDA margins of 27% in 3Q25[14,17] - Total approved policies decreased from 202,000 in 3Q24 to 186,000 in 3Q25[30] - Medicare Advantage Lifetime Value (MA LTV) decreased from $995 in 3Q24 to $915 in 3Q25[30] Healthcare Services (SelectRx) - SelectRx membership grew by 41% year-over-year, reaching nearly 106,000 members in 3Q25[14,22] - SelectRx generated nearly $675 million in trailing 12-month revenue[22]

Exhibit 99.1 SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2025 Results Third Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Fiscal Year 2025 Guidance Ranges: Third Quarter Fiscal Year 2025 – Segment Highlights Senior Healthcare Services Life OVERLAND PARK, Kan., May 12, 2025--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million compared to consolidated revenue for the third quarter of fiscal year 2 ...

Core Viewpoint - SelectQuote's stock price dropped over 19% following a lawsuit filed by the U.S. Department of Justice, alleging violations of the False Claims Act related to its business practices in the Medicare Advantage sector [1][3]. Company Investigation - Hagens Berman is investigating SelectQuote for potential misconduct regarding its sales practices and disclosures, particularly in its Senior business that offers Medicare Advantage plans [2][4]. - The investigation is focused on whether SelectQuote's claims of providing unbiased advice and comparison shopping for Medicare plans were misleading [3][4]. Allegations Against SelectQuote - The DOJ's complaint alleges that from 2016 to at least 2021, SelectQuote and other brokers received substantial payments from insurers for enrollments into Medicare Advantage plans, which may have influenced their sales practices [7]. - It is claimed that SelectQuote directed beneficiaries to plans that provided the highest kickbacks, rather than those that were most suitable for the beneficiaries [7]. - The company allegedly incentivized employees to prioritize plans based on kickbacks and discriminated against Medicare Advantage beneficiaries with disabilities [7].

Core Viewpoint - The Schall Law Firm is investigating SelectQuote, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Investigation Details - The investigation centers on claims that SelectQuote may have issued false or misleading statements and failed to disclose critical information to investors [2]. - A DOJ False Claims Act was filed against SelectQuote on May 1, 2025, alleging that from 2016 to at least 2021, insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2]. - Following the news of the investigation, SelectQuote's shares dropped by 16% on the same day [2].

Core Viewpoint - SelectQuote's share price dropped over 19% following a lawsuit filed by the U.S. Department of Justice, alleging violations of the False Claims Act related to its business practices in the Medicare Advantage market [1][3]. Group 1: Lawsuit and Allegations - The U.S. Department of Justice filed a lawsuit against SelectQuote and other insurance brokers, claiming they violated the False Claims Act [1]. - The investigation focuses on SelectQuote's disclosures regarding its sales practices, particularly in its Senior business offering Medicare Advantage plans [2]. - Allegations include that SelectQuote directed Medicare beneficiaries to plans that provided the highest kickbacks to brokers, rather than acting in the best interest of the beneficiaries [5]. Group 2: Financial Impact - Following the announcement of the lawsuit, SelectQuote's shares fell by over 19% on May 1, 2025 [1][3]. - The lawsuit raises concerns about the potential inflation of SelectQuote's financial results due to alleged steering practices [4]. Group 3: Whistleblower Information - Whistleblowers with non-public information regarding SelectQuote are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery made by the SEC [4].

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE:SLQT). The investigation concerns whether SelectQuote and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging that ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 1, 2025, the U ...

Core Points - Holzer & Holzer, LLC is investigating SelectQuote, Inc. for potential violations of federal securities laws related to a False Claims Act complaint filed by the Department of Justice [1] - The complaint alleges that SelectQuote received millions in kickbacks from Humana over six years, contingent upon specific Medicare Advantage enrollment targets and maintaining a dedicated sales force for Humana policies [1] - Following the announcement of the investigation, SelectQuote's stock price experienced a decline [1] Company Overview - SelectQuote, Inc. is publicly traded on the NYSE under the ticker SLQT [1] - The company has been implicated in a legal issue concerning its business practices and relationships with Humana [1] Legal Context - The Department of Justice's complaint highlights serious allegations of corporate misconduct involving kickbacks and improper business practices [1] - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate fraud [3]

Core Viewpoint - The U.S. Department of Justice has filed a False Claims Act complaint against SelectQuote and other health insurance companies, alleging illegal kickbacks related to Medicare Advantage plans, leading to a significant drop in SelectQuote's stock price [2]. Group 1: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against SelectQuote on behalf of its stockholders for possible violations of federal securities laws and unlawful business practices [1]. - The DOJ's complaint alleges that from 2016 to at least 2021, SelectQuote and other insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2]. Group 2: Stock Market Impact - Following the announcement of the DOJ lawsuit, SelectQuote's stock price decreased by $0.61 per share, representing a 19.24% decline, closing at $2.56 per share on May 1, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving SelectQuote, Inc. following a DOJ lawsuit alleging illegal kickbacks related to Medicare Advantage plans [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is representing investors of SelectQuote and is looking into claims of securities fraud or other unlawful practices by the company and its officers [1]. - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote and other insurers, alleging that from 2016 to 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3]. - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.24%, closing at $2.56 per share on May 1, 2025 [3]. Group 2: Company Background - SelectQuote, Inc. operates in the health insurance sector and is involved in the marketing of Medicare Advantage plans [3]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].